CAH RSI Chart
Last 7 days
-4.6%
Last 30 days
-11.0%
Last 90 days
-5.1%
Trailing 12 Months
15.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 220.6B | 0 | 0 | 0 |
2023 | 198.7B | 205.0B | 210.2B | 216.1B |
2022 | 176.8B | 181.4B | 187.0B | 193.0B |
2021 | 156.6B | 162.5B | 167.4B | 171.3B |
2020 | 153.6B | 152.9B | 154.6B | 156.5B |
2019 | 143.5B | 145.5B | 147.7B | 149.7B |
2018 | 134.4B | 136.8B | 139.4B | 141.9B |
2017 | 128.4B | 130.0B | 130.6B | 132.6B |
2016 | 117.7B | 121.5B | 125.5B | 127.2B |
2015 | 97.9B | 102.5B | 106.5B | 112.4B |
2014 | 93.6B | 91.1B | 90.6B | 93.9B |
2013 | 102.4B | 101.1B | 99.7B | 96.7B |
2012 | 107.6B | 107.6B | 106.6B | 104.8B |
2011 | 100.3B | 102.6B | 105.0B | 106.7B |
2010 | 98.4B | 98.5B | 98.2B | 98.6B |
2009 | 93.8B | 96.0B | 97.3B | 98.1B |
2008 | 0 | 87.4B | 89.6B | 91.7B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 15, 2024 | greene michelle d. | sold (taxes) | -72,993 | 109 | -664 | chief information officer |
Mar 15, 2024 | azelby robert | acquired | - | - | 1,288 | - |
Feb 15, 2024 | alt aaron e | sold (taxes) | -198,712 | 103 | -1,919 | chief financial officer |
Feb 15, 2024 | greene michelle d. | sold (taxes) | -68,757 | 103 | -664 | chief information officer |
Dec 01, 2023 | weitzman deborah | sold (taxes) | -68,317 | 107 | -638 | ceo, pharmaceutical segment |
Dec 01, 2023 | snow ola m | sold (taxes) | -40,904 | 107 | -382 | chief human resources officer |
Dec 01, 2023 | scherer mary c. | sold (taxes) | -23,236 | 107 | -217 | chief accounting officer |
Nov 27, 2023 | weitzman deborah | acquired | 2,048,360 | 74.103 | 27,642 | ceo, pharmaceutical segment |
Nov 27, 2023 | weitzman deborah | sold | -3,895,410 | 106 | -36,642 | ceo, pharmaceutical segment |
Nov 15, 2023 | hall patricia hemingway | acquired | - | - | 1,965 | - |
Which funds bought or sold CAH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | M&T Bank Corp | added | 32.12 | 831,101 | 2,611,440 | 0.01% |
May 07, 2024 | ASSETMARK, INC | reduced | -55.04 | -2,869,770 | 2,859,810 | 0.01% |
May 07, 2024 | Cornerstone Planning Group LLC | added | 0.67 | -428 | 29,812 | 0.01% |
May 07, 2024 | Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | added | 9.25 | 256,752 | 1,463,460 | 0.04% |
May 07, 2024 | Gibraltar Capital Management, Inc. | sold off | -100 | -769,306 | - | -% |
May 07, 2024 | Headlands Technologies LLC | reduced | -98.66 | -177,544 | 2,686 | -% |
May 07, 2024 | MEEDER ASSET MANAGEMENT INC | new | - | 7,050 | 7,050 | -% |
May 07, 2024 | First Heartland Consultants, Inc. | sold off | -100 | -275,000 | - | -% |
May 07, 2024 | Williams Jones Wealth Management, LLC. | new | - | 231,633 | 231,633 | -% |
May 07, 2024 | Legacy Capital Group California, Inc. | added | 60.95 | 844,949 | 1,918,970 | 0.71% |
Unveiling Cardinal Health Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cardinal Health Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 182.6B | 40.3B | 32.45 | 4.53 | ||||
BDX | 67.4B | 19.7B | 50.6 | 3.42 | ||||
ALGN | 20.6B | 3.9B | 44.54 | 5.26 | ||||
BAX | 18.2B | 14.9B | 6.88 | 1.22 | ||||
MID-CAP | ||||||||
ATR | 10.0B | 3.5B | 31.94 | 2.82 | ||||
HSIC | 9.3B | 12.5B | 24.01 | 0.75 | ||||
BIO | 7.6B | 2.6B | -23.72 | 2.94 | ||||
XRAY | 5.8B | 3.9B | -61.76 | 1.47 | ||||
AXNX | 3.4B | 387.1M | -215.56 | 8.87 | ||||
PDCO | 2.3B | 6.6B | 11.98 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.85 | 0.4 | ||||
ANIK | 423.5M | 166.7M | -5.12 | 2.54 | ||||
ANGO | 236.7M | 324.0M | -1.23 | 0.73 | ||||
APYX | 45.4M | 52.3M | -2.43 | 0.87 | ||||
AEMD | 3.3M | 3.7M | -0.27 | 0.88 |
Cardinal Health Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -4.4% | 54,911 | 57,445 | 54,763 | 53,453 | 50,487 | 51,469 | 49,603 | 47,103 | 44,836 | 45,457 | 43,968 | 42,586 | 39,275 | 41,541 | 39,065 | 36,689 | 39,157 | 39,735 | 37,341 | 37,353 | 35,228 |
Gross Profit | 5.5% | 1,947 | 1,846 | 1,768 | 1,827 | 1,785 | 1,663 | 1,614 | 1,605 | 1,682 | 1,616 | 1,642 | 1,475 | 1,812 | 1,776 | 1,715 | 1,590 | 1,885 | 1,714 | 1,679 | 1,674 | 1,764 |
S&GA Expenses | -0.1% | 1,282 | 1,283 | 1,197 | 1,267 | 1,179 | 1,191 | 1,197 | 1,155 | 1,137 | 1,151 | 1,114 | 1,129 | 1,120 | 1,147 | 1,137 | 1,137 | 1,165 | 1,163 | 1,107 | 1,168 | 1,097 |
EBITDA Margin | -12.2% | 0.01* | 0.01* | 0.01* | 0.01* | 0.01* | 0.00* | 0.00* | 0.00* | 0.00* | 0.00* | 0.01* | 0.01* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 312.5% | 33.00 | 8.00 | 14.00 | 15.00 | 28.00 | 25.00 | 25.00 | 34.00 | 38.00 | 37.00 | 40.00 | 44.00 | 45.00 | 46.00 | 45.00 | 49.00 | 60.00 | 63.00 | 66.00 | 67.00 | 75.00 |
Income Taxes | -39.7% | 82.00 | 136 | -32.00 | 187 | 197 | -7.00 | -1.00 | -165 | 1,253 | -1,022 | 97.00 | 4.00 | 320 | -203 | -410 | 107 | -127 | -59.00 | -423 | 44.00 | 74.00 |
Earnings Before Taxes | -30.4% | 341 | 490 | -26.00 | 121 | 544 | -137 | 110 | -28.00 | -137 | -973 | 369 | 119 | 440 | 427 | -663 | 815 | 478 | 279 | -5,344 | 239 | 370 |
EBT Margin | -19.6% | 0.00* | 0.01* | 0.00* | 0.00* | 0.00* | 0.00* | -0.01* | 0.00* | 0.00* | 0.00* | 0.01* | 0.00* | - | - | - | - | - | - | - | - | - |
Net Income | -26.9% | 258 | 353 | 5.00 | -64.00 | 345 | -130 | 110 | 138 | -1,391 | 49.00 | 271 | 116 | 119 | 629 | -253 | 656 | 350 | 220 | -4,922 | 194 | 296 |
Net Income Margin | -15.3% | 0.00* | 0.00* | 0.00* | 0.00* | 0.00* | -0.01* | -0.01* | -0.01* | -0.01* | 0.00* | 0.01* | 0.00* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -115.0% | -161 | 1,075 | 453 | 641 | 1,252 | 512 | -47.00 | 2,828 | -501 | 1,121 | -713 | 539 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.5% | 45,880 | 46,573 | 43,710 | 43,417 | 43,377 | 44,482 | 43,387 | 43,878 | 42,111 | 43,680 | 42,993 | 44,453 | 43,874 | 44,719 | 41,727 | 40,766 | 41,148 | 41,042 | 39,179 | 40,963 | 40,809 |
Current Assets | -5.1% | 35,734 | 37,658 | 34,688 | 33,833 | 33,497 | 34,596 | 32,696 | 32,935 | 30,884 | 31,847 | 29,731 | 31,048 | 30,362 | 30,113 | 27,030 | 25,940 | 25,848 | 25,736 | 23,715 | 25,747 | 25,582 |
Cash Equivalents | -19.0% | 3,718 | 4,591 | 3,854 | 4,043 | 3,990 | 3,654 | 3,492 | 4,717 | 2,356 | 3,161 | 2,463 | 3,407 | 3,499 | 3,737 | 2,746 | 2,771 | 2,329 | 1,659 | 1,212 | 2,531 | 3,438 |
Inventory | -6.4% | 17,277 | 18,451 | 16,987 | 15,940 | 16,620 | 17,263 | 15,891 | 15,636 | 15,493 | 14,941 | 14,720 | 14,594 | 14,329 | 14,443 | 13,439 | 13,198 | 12,808 | 13,799 | 12,458 | 12,822 | 12,622 |
Net PPE | 1.0% | 2,470 | 2,446 | 2,441 | 2,462 | 2,362 | 2,341 | 2,339 | 2,361 | 2,298 | 2,321 | 2,336 | 2,360 | 2,315 | 2,386 | 2,369 | 2,366 | 2,299 | 2,301 | 2,324 | 2,356 | 2,322 |
Current Liabilities | -5.2% | 36,306 | 38,286 | 35,065 | 33,706 | 32,503 | 33,212 | 31,559 | 30,550 | 28,715 | 27,729 | 26,499 | 27,624 | 25,323 | 25,750 | 24,016 | 23,615 | 24,671 | 24,890 | 22,549 | 24,109 | 23,919 |
Long Term Debt | 32.0% | 4,667 | 3,535 | 3,890 | 3,909 | 4,708 | 4,685 | 4,689 | 4,735 | 4,751 | 5,342 | 5,353 | 5,365 | 6,715 | 6,720 | 6,728 | 6,765 | 6,754 | 6,742 | 7,360 | 7,579 | 7,629 |
Shareholder's Equity | 5.4% | -3,262 | -3,447 | - | -2,851 | -2,218 | -2,212 | - | -706 | - | 1,002 | 1,396 | 1,794 | 1,794 | 1,975 | 1,425 | 1,792 | 1,206 | 1,002 | 903 | 6,330 | 6,232 |
Retained Earnings | 32.0% | -289 | -425 | -654 | -534 | -342 | -560 | -301 | -280 | -281 | 1,245 | 1,335 | 1,205 | 1,233 | 1,255 | 771 | 1,170 | 656 | 449 | 371 | 5,434 | 5,386 |
Shares Outstanding | -1.6% | 243 | 247 | 249 | 261 | 256 | 261 | 271 | 279 | 281 | 283 | 287 | 292 | - | - | - | - | - | - | - | - | - |
Minority Interest | 50.0% | 3.00 | 2.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 |
Float | - | - | - | - | - | - | 19,775 | - | - | - | 14,224 | - | - | - | 15,694 | - | - | - | 14,729 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -104.1% | -49.00 | 1,189 | 545 | 858 | 1,361 | 597 | 23.00 | 2,992 | -419 | 1,195 | -646 | 665 | 277 | 1,217 | 270 | 240 | 1,676 | 697 | -653 | 506 | 1,480 |
Share Based Compensation | 10.7% | 31.00 | 28.00 | 29.00 | 27.00 | 21.00 | 25.00 | 23.00 | 16.00 | 23.00 | 18.00 | 24.00 | 5.00 | 33.00 | 23.00 | 28.00 | 22.00 | 27.00 | 21.00 | 20.00 | 18.00 | 23.00 |
Cashflow From Investing | -1659.0% | -1,847 | -105 | -63.00 | -206 | -91.00 | -87.00 | -70.00 | -204 | -44.00 | -47.00 | 862 | -88.00 | -99.00 | -97.00 | -94.00 | 742 | -98.00 | -78.00 | -73.00 | -173 | -84.00 |
Cashflow From Financing | 392.1% | 1,031 | -353 | -666 | -592 | -934 | -362 | -1,163 | -415 | -340 | -444 | -1,264 | -649 | -324 | -146 | -198 | -528 | -912 | -175 | -585 | -1,243 | -142 |
Dividend Payments | -100.0% | - | 124 | 131 | 126 | 128 | 129 | 142 | 134 | 136 | 140 | 149 | 141 | 143 | 143 | 146 | 141 | 141 | 141 | 146 | 142 | 142 |
Buy Backs | -25.0% | 75.00 | 100 | 500 | 650 | 50.00 | 150 | 1,000 | 220 | 20.00 | 40.00 | 500 | - | 200 | - | - | - | -35.00 | 70.00 | 350 | - | - |
Condensed Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||||
Revenue | $ 54,911 | $ 50,487 | $ 167,119 | $ 151,559 |
Cost of products sold | 52,964 | 48,702 | 161,558 | 146,497 |
Gross margin | 1,947 | 1,785 | 5,561 | 5,062 |
Operating expenses: | ||||
Distribution, selling, general and administrative expenses | 1,282 | 1,179 | 3,762 | 3,567 |
Restructuring and employee severance | 53 | 16 | 106 | 62 |
Amortization and other acquisition-related costs | 80 | 74 | 207 | 216 |
Impairments and (gain)/loss on disposal of assets, net | 84 | 20 | 622 | 883 |
Litigation (recoveries)/charges, net | 81 | (76) | 29 | (256) |
Operating earnings | 367 | 572 | 835 | 590 |
Other (income)/expense, net | (7) | 0 | (25) | (5) |
Interest expense, net | 33 | 28 | 55 | 78 |
Earnings/(loss) before income taxes | 341 | 544 | 805 | 517 |
Provision for income taxes | 82 | 197 | 186 | 189 |
Net earnings/(loss) | 259 | 347 | 619 | 328 |
Less: Net earnings attributable to noncontrolling interests | (1) | (2) | (3) | (3) |
Net earnings attributable to Cardinal Health, Inc. | $ 258 | $ 345 | $ 616 | $ 325 |
Earnings per common share attributable to Cardinal Health, Inc.: | ||||
Basic (in shares) | $ 1.06 | $ 1.35 | $ 2.51 | $ 1.24 |
Diluted (in shares) | $ 1.05 | $ 1.34 | $ 2.49 | $ 1.23 |
Weighted-average number of common shares outstanding: | ||||
Basic (in shares) | 243 | 256 | 245 | 263 |
Diluted (in shares) | 245 | 258 | 247 | 264 |
Cash dividends declared per common share | $ 0.5006 | $ 0.4957 | $ 1.5018 | $ 1.4871 |
Condensed Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Millions | Mar. 31, 2024 | Jun. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and equivalents | $ 3,718 | $ 4,043 |
Trade receivables, net | 11,566 | 11,344 |
Inventories, net | 17,277 | 15,940 |
Prepaid expenses and other | 3,161 | 2,362 |
Assets held for sale | 12 | 144 |
Total current assets | 35,734 | 33,833 |
Property and equipment, net | 2,470 | 2,462 |
Goodwill and other intangibles, net | 6,507 | 6,081 |
Other assets | 1,169 | 1,041 |
Total assets | 45,880 | 43,417 |
Current liabilities: | ||
Accounts payable | 32,089 | 29,813 |
Current portion of long-term obligations and other short-term borrowings | 1,187 | 792 |
Other accrued liabilities | 3,030 | 3,059 |
Liabilities related to assets held for sale | 0 | 42 |
Total current liabilities | 36,306 | 33,706 |
Long-term obligations, less current portion | 4,667 | 3,909 |
Deferred income taxes and other liabilities | 8,169 | 8,653 |
Preferred shares, without par value: | ||
Authorized—500 thousand shares, Issued—none | 0 | 0 |
Common shares, without par value: | ||
Authorized—755 million shares, Issued—327 million shares at March 31, 2024 and June 30, 2023 | 2,887 | 2,747 |
Accumulated deficit | (289) | (534) |
Common shares in treasury, at cost: 83 million shares and 76 million shares at March 31, 2024 and June 30, 2023, respectively | (5,703) | (4,914) |
Accumulated other comprehensive loss | (160) | (151) |
Total Cardinal Health, Inc. shareholders' deficit | (3,265) | (2,852) |
Noncontrolling interests | 3 | 1 |
Total shareholders’ deficit | (3,262) | (2,851) |
Total liabilities and shareholders’ deficit | $ 45,880 | $ 43,417 |
Preferred shares, authorized | 500 | 500 |
Preferred shares, issued | 0 | 0 |
Common shares, authorized | 755,000 | 755,000 |
Common shares, issued | 327,000 | 327,000 |
Common shares in treasury | 83,000 | 76,000 |